Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly
Status:
Withdrawn
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This randomized clinical trial will address a complication related to recurrent episodes of
malaria in endemic areas - hyper-reactive malarial splenomegaly. We aim to assess the
efficacy of chloroquine after prednisone-induction therapy compared to standard treatment of
chloroquine alone in the treatment of adult patients with newly diagnosed hyper-reactive
malarial splenomegaly.
Phase:
Phase 3
Details
Lead Sponsor:
Lihir Medical Centre
Treatments:
Chloroquine Chloroquine diphosphate Immunoglobulin M Prednisone